Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(104)
•••
Comment by foofadoooon Oct 01, 2015 7:36am
205 Views
Post# 24152392

RE:RE:nice 4050 News out...

RE:RE:nice 4050 News out...The fog is lifting and the track is clear .... 
ProMetic allowed to proceed with filing of IND for pivotal study ahead of anticipated timelines - PBI-4050 to be added in combination to commercially available drugs in pivotal study
Read more at https://www.stockhouse.com/news/press-releases/2015/10/01/prometic-reports-successful-pbi-4050-pre-ind-meeting-with-the-us-fda-for#1SiGhwk1zbsigzvf.99

"To date, PBI-4050 has presented a remarkable safety and tolerability profile throughout our phase I trials and ongoing phase II clinical trial", said Mr. Pierre Laurin, CEO of ProMetic. "The objective of this pivotal trial is to demonstrate that PBI-4050 can safely provide significant additional clinical benefits to IPF patients and we appreciate the input of the FDA regarding the design of the trial".
Read more at https://www.stockhouse.com/news/press-releases/2015/10/01/prometic-reports-successful-pbi-4050-pre-ind-meeting-with-the-us-fda-for#1SiGhwk1zbsigzvf.99
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities